Adjuvance Overview
- Founded
-
2009
- Status
-
Out of Business
- Employees
-
18
- Latest Deal Type
-
Out of Business
Adjuvance General Information
Description
Developer of a biopharmaceutical platform designed to improve health and save lives through the development of vaccine adjuvant. The company's platform is based on SAPONEX products that are critical components to many vaccines for multiple indications in infectious disease, oncology, neurobiology, substance abuse, and allergy, enabling patients to improve their immune systems.
Contact Information
Website
www.adjuvancetechnologies.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 1225 L Street
- Suite 600
- Lincoln, NE 68508
- United States
Adjuvance Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Out of Business | 20-Apr-2022 | 000.00 | Completed | Out of Business | ||
| 6. Grant | 19-May-2020 | 00.000 | 000.00 | Completed | Pre-Clinical Trials | |
| 5. Later Stage VC (Series A1) | 29-Jan-2020 | 0000 | 000.00 | 0000 | Completed | Pre-Clinical Trials |
| 4. Grant | 01-Jan-2020 | 00000 | 00.00 | Completed | Pre-Clinical Trials | |
| 3. Seed Round | 29-Aug-2019 | 00.00 | 00.00 | Completed | Pre-Clinical Trials | |
| 2. Grant | 01-Mar-2017 | $1.5M | Completed | Pre-Clinical Trials | ||
| 1. Grant | 01-Jan-2017 | $448K | Completed | Pre-Clinical Trials |
Adjuvance Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-1 | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A-2 | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Adjuvance Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Developer of a biopharmaceutical platform designed to improve health and save lives through the development of vaccine a
Drug Discovery
Lincoln, NE
18
As of 2022
000.00
00000000 00
000.00
000000
rem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor inc
0000000000000
Emeryville, CA
000
As of 0000
00000
000000000
00000
000000
laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in repre
0000000000000
Gaithersburg, MD
0000
As of 0000
00000
000000000
00000
Add Comparison
Adjuvance Competitors (3)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dynavax Technologies | Corporation | Emeryville, CA | 000 | 00000 | 000000000 | 00000 |
| 0000000 | Corporation | Gaithersburg, MD | 0000 | 00000 | 000000000 | 00000 |
| 000000000000000 00 | Corporation | Saint-Amand-Les-Eaux, France |
Adjuvance Patents
Adjuvance Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020379738-A1 | Varicella zoster | Pending | 05-Nov-2019 | 000000000 | |
| CA-3157372-A1 | Varicella zoster | Pending | 05-Nov-2019 | 000000000 | |
| US-20220409721-A1 | Varicella zoster | Pending | 05-Nov-2019 | 000000000 | |
| EP-4054616-A1 | Varicella zoster | Pending | 05-Nov-2019 | 000000000 | |
| US-20200261571-A1 | Triterpene saponin analogues | Active | 16-Oct-2017 | A61P37/04 |
Adjuvance Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
